Zacks Investment Management Sells 33,347 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Zacks Investment Management decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 11.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 254,662 shares of the biotechnology company's stock after selling 33,347 shares during the quarter. Zacks Investment Management owned 0.11% of ADMA Biologics worth $4,367,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Perpetual Ltd bought a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $62,300,000. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics in the 3rd quarter worth about $61,858,000. Allspring Global Investments Holdings LLC raised its position in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter valued at about $19,076,000. Finally, Principal Financial Group Inc. grew its holdings in shares of ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Trading Up 3.3 %

Shares of NASDAQ:ADMA traded up $0.70 during midday trading on Wednesday, reaching $22.09. The company's stock had a trading volume of 1,497,713 shares, compared to its average volume of 3,620,677. The firm has a 50 day moving average price of $18.44 and a two-hundred day moving average price of $18.23. ADMA Biologics, Inc. has a fifty-two week low of $6.23 and a fifty-two week high of $23.64. The firm has a market capitalization of $5.22 billion, a price-to-earnings ratio of 78.89 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.